BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19901198)

  • 21. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
    Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
    Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
    Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
    Arifin SA; Paternoster S; Carlessi R; Casari I; Ekberg JH; Maffucci T; Newsholme P; Rosenkilde MM; Falasca M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1132-1141. PubMed ID: 29883799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder.
    Zhang S; Ma Y; Li J; Ma J; Yu B; Xie X
    Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14571-6. PubMed ID: 25246581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-OMe-lysophosphatidylcholine analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells: Evaluation of structure-dependent biological activity.
    Drzazga A; Sowińska A; Krzemińska A; Okruszek A; Paneth P; Koziołkiewicz M; Gendaszewska-Darmach E
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):91-103. PubMed ID: 29079451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.
    Hassing HA; Engelstoft MS; Sichlau RM; Madsen AN; Rehfeld JF; Pedersen J; Jones RM; Holst JJ; Schwartz TW; Rosenkilde MM; Hansen HS
    Biofactors; 2016 Nov; 42(6):665-673. PubMed ID: 27297962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119.
    Park EY; Kim EH; Kim CY; Kim MH; Choung JS; Oh YS; Moon HS; Jun HS
    PLoS One; 2016; 11(7):e0158796. PubMed ID: 27391814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia.
    Li NX; Brown S; Kowalski T; Wu M; Yang L; Dai G; Petrov A; Ding Y; Dlugos T; Wood HB; Wang L; Erion M; Sherwin R; Kelley DE
    Diabetes; 2018 Jul; 67(7):1401-1413. PubMed ID: 29669745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
    Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
    PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes.
    Patel S; Mace OJ; Tough IR; White J; Cock TA; Warpman Berglund U; Schindler M; Cox HM
    Int J Obes (Lond); 2014 Oct; 38(10):1365-73. PubMed ID: 24451185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
    Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
    Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.
    Lauffer LM; Iakoubov R; Brubaker PL
    Diabetes; 2009 May; 58(5):1058-66. PubMed ID: 19208912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119.
    Hassing HA; Fares S; Larsen O; Pad H; Hauge M; Jones RM; Schwartz TW; Hansen HS; Rosenkilde MM
    Biochem Pharmacol; 2016 Nov; 119():66-75. PubMed ID: 27569424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo.
    Huan Y; Jiang Q; Li G; Bai G; Zhou T; Liu S; Li C; Liu Q; Sun S; Yang M; Guo N; Wang X; Wang S; Liu Y; Wang G; Huang H; Shen Z
    Sci Rep; 2017 Jun; 7(1):4351. PubMed ID: 28659588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
    Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.